LEXX 8-K
Lexaria Bioscience Corp. (LEXX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter) |
|
| ||||||||||||||||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) | |||||||||||||
| ||||||
(Address of principal executive offices) |
| (Zip Code) | ||||
Registrant’s telephone number, including area code (
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
Receipt of Australian R & D Tax Incentive Credit
On August 28, 2026, Lexaria (AU) Pty Ltd, the wholly-owned subsidiary of Lexaria Bioscience Corp. which holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in the territory of Australia, received a tax credit in the amount of AUD$3,666,611.98 (USD$2.6M), from the Australian Tax Office (the “Credit”) in connection with the research and development costs associated with its Australian clinical study GLP-1-H24-4.
The Credit has been deposited into the Australian bank account of Lexaria (AU) Pty Ltd for the intended purpose of pursuing additional research and development opportunities in Australia.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP. | |||
| Date: September 1, 2026 | By: | /s/ Richard Christopher | |
|
| Richard Christopher | |
CEO, Principal Executive Officer | |||
| 3 |